Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fasting and Withholding Dulaglutide on Gastric Contents in T2DM
NCT07313813Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Fasting Participants with Lack of Gastric Content Retention Post-Solid Test Meal at Day 116. Started Dec 2025; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07313813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313813.